343 terminated. 343 Phase 2, 78 Phase 1, 17 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 343 | Terminated 343 |
| Phase 1 | 78 | Terminated 78 |
| Phase 3 | 17 | Terminated 17 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer PD-1 vaccine IMU-201 (PD1-Vaxx) - Colorectal Cancer | Phase 2 | Terminated | University of Southampton | 3 | 2025-06-16 | 2026-06-24 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis SAR441566, SAR441566 matching Placebo - Colitis Ulcerative | Phase 2 | Terminated | Sanofi | 170 | 2025-03-28 | 2026-10-21 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers AUR109 200mg, AUR109 300mg, AUR109 400mg - Ovarian Cancer, Colorectal Cancer | Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 29 | 2024-11-09 | 2026-04-17 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) Vixarelimab, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Genentech, Inc. | 79 | 2024-05-01 | 2026-02-24 |
| Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). CIN-103, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 2 | Terminated | CinPhloro Pharma, LLC | 421 | 2023-12-28 | 2025-12-15 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2023-11-09 | 2025-07-22 |
| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer KN046, regorafenib - Colorectal Cancer | Phase 2 | Terminated | Peking University Cancer Hospital & Institute | 20 | 2023-10-26 | 2026-11-03 |
| A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer Ompenaclid, Placebo, Bevacizumab - Colorectal Cancer, Metastatic Colon Cancer | Phase 2 | Terminated | Inspirna, Inc. | 76 | 2023-10-10 | 2026-02-20 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| VE202 in Patients With Mild-to-Moderate Ulcerative Colitis VE202, Vancomycin Oral Capsule, VE202 Placebo - Ulcerative Colitis, Colitis, Ulcerative | Phase 2 | Terminated | Vedanta Biosciences, Inc. | 114 | 2023-05-08 | 2025-12-17 |
| Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis Efavaleukin alfa, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Amgen | 25 | 2023-04-28 | 2025-10-15 |
| TATE and KN046 in MCRC KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization - Colorectal Cancer with Hepatic Metastases | Phase 2 | Terminated | Zhejiang Raygene Pharmaceuticals Co., Ltd | 42 | 2023-04-27 | 2025-02-19 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis | Phase 2 | Terminated | AbbVie | 81 | 2023-04-24 | 2026-06-15 |
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors Revumenib, Chemotherapy - Colorectal Cancer, Solid Tumors | Phase 1 / Phase 2 | Terminated | Syndax Pharmaceuticals | 41 | 2023-04-04 | 2026-07-06 |
| EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer EO2040 - Colorectal Cancer | Phase 2 | Terminated | Enterome | 1 | 2023-03-01 | 2025-09-29 |
| Electroporation and Immunotherapy in Metastatic Colorectal Cancer Irreversible electroporation, Calcium electroporation, Pembrolizumab - Metastatic Colorectal Cancer | Phase 2 | Terminated | Ismail Gögenur | 4 | 2023-01-26 | 2024-06-03 |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy - Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2023-01-19 | 2026-05-14 |
Showing 20 of 343. Sign in to see all of them.
Colorectal Neoplasms (231) · Colonic Neoplasms (77) · Colitis, Ulcerative (61) · Rectal Neoplasms (49) · Neoplasm Metastasis (39) · Carcinoma, Non-Small-Cell Lung (25) · Breast Neoplasms (24) · Neoplasms (23) · Stomach Neoplasms (21) · Pancreatic Neoplasms (20) · Ovarian Neoplasms (19) · Esophageal Neoplasms (14) · Irritable Bowel Syndrome (13) · Lung Neoplasms (13) · Head and Neck Neoplasms (11)
Digestive System Diseases (340) · Intestinal Diseases (340) · Gastrointestinal Diseases (339) · Neoplasms by Site (265) · Digestive System Neoplasms (264) · Intestinal Neoplasms (264) · Gastrointestinal Neoplasms (259) · Neoplasms (248) · Rectal Diseases (247) · Gastroenteritis (63) · Colitis (59) · Pathological Conditions, Signs and Symptoms (53) · Inflammatory Bowel Diseases (52) · Pathologic Processes (46)
Irinotecan (48) · Bevacizumab (45) · Fluorouracil (41) · Leucovorin (40) · Oxaliplatin (40) · Capecitabine (38) · Cetuximab (33) · pembrolizumab (10) · regorafenib (10) · IFL protocol (9) · Nivolumab (9) · Panitumumab (9) · Radiotherapy (7) · Drug Therapy (6) · Cyclophosphamide (5)
National Cancer Institute (NCI) (17) · Georgetown University (7) · Pfizer (7) · M.D. Anderson Cancer Center (6) · Roswell Park Cancer Institute (6) · Gilead Sciences (5) · Hoffmann-La Roche (5) · Novartis Pharmaceuticals (5) · AstraZeneca (4) · Incyte Corporation (4) · Sanofi (4) · Alliance for Clinical Trials in Oncology (3) · Amgen (3) · Brown University (3) · City of Hope Medical Center (3)
United States (228) · France (56) · Germany (47) · Spain (43) · Italy (38) · Belgium (37) · Canada (32) · Poland (32) · South Korea (30) · Australia (29) · United Kingdom (26) · Czechia (21) · Hungary (21) · Netherlands (20) · Ukraine (20)
Marwan Fakih, MD (3) · Dominique Elias, MD (2) · Harish Dave (2) · John L Marshall, MD (2)
PMID 28712102, PMID 31527168, PMID 17945036, PMID 18197583, PMID 20947884, PMID 21453880, PMID 21516509, PMID 22294255, PMID 22431703, PMID 23443801, PMID 24244261, PMID 24244687, PMID 26109878, PMID 26119226, PMID 27784746, PMID 28246207, PMID 28424071, PMID 30120161, PMID 30131226, PMID 30514262, PMID 30552157, PMID 30858085, PMID 31331370, PMID 31401903, PMID 31982148, PMID 32143730, PMID 32816630, PMID 33016924, PMID 33207247, PMID 34474038, PMID 34696309, PMID 35014040, PMID 35444059, PMID 35537408, PMID 35623069, PMID 35920133, PMID 36740814, PMID 37323059, PMID 37678921, PMID 38184304, PMID 38309721, PMID 38582964, PMID 39563886, PMID 39652198, PMID 39676137, PMID 39791563, PMID 39793589, PMID 40632975, PMID 41171165, PMID 41342324
2017 (8), 2019 (6), 2018 (5), 2009 (3), 2014 (3), 2015 (3), 2023 (3), P30CA016672 (3), 2016 (2), 2025 (2), P30CA015704 (2), P30CA060553 (2), 2005 (1), N01CM17003 (1), N01CM62202 (1)